Cidara Therapeutics (NASDAQ:CDTX) Rating Reiterated by Cantor Fitzgerald

Cidara Therapeutics (NASDAQ:CDTX)‘s stock had its “overweight” rating restated by equities research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Tuesday, Benzinga reports.

Separately, HC Wainwright restated a “buy” rating and set a $120.00 price objective on shares of Cidara Therapeutics in a research note on Monday, April 8th. One equities research analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $93.33.

Cidara Therapeutics Price Performance

Shares of CDTX opened at $12.29 on Tuesday. The business’s fifty day moving average price is $15.40 and its 200 day moving average price is $15.35. Cidara Therapeutics has a 12-month low of $10.00 and a 12-month high of $29.60. The stock has a market capitalization of $1.11 billion, a PE ratio of -51.21 and a beta of 0.98.

Institutional Investors Weigh In On Cidara Therapeutics

A number of hedge funds have recently added to or reduced their stakes in CDTX. Flagship Harbor Advisors LLC bought a new stake in shares of Cidara Therapeutics during the third quarter valued at about $28,000. Pale Fire Capital SE bought a new stake in shares of Cidara Therapeutics during the third quarter valued at about $51,000. Finally, Raymond James Financial Services Advisors Inc. raised its stake in shares of Cidara Therapeutics by 25.2% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 79,119 shares of the biotechnology company’s stock valued at $75,000 after purchasing an additional 15,912 shares in the last quarter. 35.82% of the stock is currently owned by institutional investors.

About Cidara Therapeutics

Cidara Therapeutics, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.